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Abstract
Background: Melanoma is the most aggressive form of skin cancer and the most rapidly expanding cancer in
terms of worldwide incidence. Chemotherapeutic approaches to treat melanoma have had only marginal success.
Previous studies in mice demonstrated that a high diluted complex derived from Calcarea carbonica (M8)
stimulated the tumoricidal response of activated lymphocytes against B16F10 melanoma cells in vitro.
Methods: Here we describe the in vitro inhibition of invasion and the in vivo anti-metastatic potential after M8
treatment by inhalation in the B16F10 lung metastasis model.
Results: We found that M8 has at least two functions, acting as both an inhibitor of cancer cell adhesion and
invasion and as a perlecan expression antagonist, which are strongly correlated with several metastatic, angiogenic
and invasive factors in melanoma tumors.
Conclusion: The findings suggest that this medication is a promising non-toxic therapy candidate by improving
the immune response against tumor cells or even induce direct dormancy in malignancies.
Background
Melanoma represents a significant worldwide public
health risk and, from the standpoint of incidence, is the
fastest growing of all cancer types. Malignnant mela-
noma is the most aggressive form of skin cancer, with a
mortality rate that has risen about 2% annually since
1960. Although early stage melanoma can be cured sur-
gically, once melanoma metastasizes to major organs
(stage IV), it is almost always incurable [1]. There are
few chemotherapeutic agents available for treating meta-
static melanoma, and those that have been used have all
yielded unsatisfactory results. No single chemotherapeu-
tic agent currently offers a response rate greater than
25%, and treatment is invariably accompanied by signifi-
cant side effects, including myelosuppression, nausea
and emesis [2-4].
Malignant transformation could be associated with
general enzymatic changes leading to increased proteo-
lytic and fibrinolytic activity in tumor cells. The signifi-
cance of angiogenesis in tumor development and
metastasis is well established, and it was previously con-
firmed that a significant correlation exists between
tumor angiogenesis and the ability of a melanoma to
metastasize [5]. It has been observed that heparan sul-
fate proteoglycan expression, especially perlecan expres-
sion, is a prerequisite for melanoma tumor growth and
metastasis [6,7].
Immunotherapy remains the subject of intense investi-
gation in both adjuvant and advanced disease settings,
and attempts are being made to target melanoma
defense mechanisms that blunt the effectiveness of host
immune responses [8]. Many natural compounds have
been extensively studied to determine a possible anti-
tumor effect. Our previous studies have demonstrated
that a high diluted natural complex activates macro-
phages both in vivo and in vitro [9-11]. Moreover, that
natural complex was neither toxic nor mutagenic [12].
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treated mice has been demonstrated in studies with Sar-
coma-180, including a significant infiltration of lym-
phoid cells, granulated tissue, fibrosis development
around the tumor, sarcoma size reduction and an
increase in the number of circulating leukocytes, such as
B, NK and CD4
+ cells [13]. These results suggest that
the medication has a direct or indirect action on hema-
topoiesis. A subsequent microscopic study of bone mar-
row cells showed that monocytic lineage (CD11b
+)a n d
stromal cells (adherent cells) were activated by treat-
ment [14-16]. A previous study with an in vitro model
showed that a specific high diluted complex derived
from Calcarea carbonica and associations (here defined
as M8 in the Materials and Methods section) activated
lymphocytes even without direct contact with macro-
phages. A co-culture with macrophages and lympho-
cytes in the presence of M8 promoted stimulation of
lymphocytes, resulting in an enhanced tumoricidal per-
formance against a very aggressive lineage of melanoma
cells [17].
We previously reported that M8 showed a promising
capacity to stimulate immune cells against melanoma
cells in vitro. In the present work we aimed to study the
effects of M8 in vivo using a melanoma metastasis
mouse model. We assessed blood and bone marrow
cells immunophenothyping, tumor histopathology,
immunohistochemistry, and ultrastructural analysis.
Methods
M8 complex
High diluted natural complexes represent a new form of
immunomodulatory therapy and follow Hahnemann’s
ancient homeopathic techniques for dilution. Mother
tinctures were purchased from authorized agencies sanc-
tioned by the Brazilian Health Ministry. These agencies
assure the quality (endotoxin free) and physico-chemical
composition of their products. Starting from the original
mother tincture – an ethanolic extract in this case –
several dynamizations/succussion (shaking) and serial
dilutions in distilled water were performed. The medica-
tion used to treat in vitro and in vivo models was a
complex matrix obtained from Calcarea carbonica CH5
with associations, comprised of a 10%-20% concentra-
tion of each compound obtained after vigorous shaking.
In addition to Calcarea carbonica,t h ef i n a ls o l u t i o n
contained Aconitum napellus, Arsenicum album, Asa
foetida, Conium maculatum, Ipecacuanha, Phosphorus,
Rhus tox, Silicea, Sulphur,a n dThuya occidentalis,a l li n
decimal dilutions of Hahnemann (dH) in distilled water.
The resulting aqueous solution was colorless and odor-
less, and had 1% alcohol concentration. This complex as
well its vehicle (hydroalcoholic solution) used as control
were sterilized by filtration through 0.22 μm MILLEX
GV Durapore PVDF membranes (Millipore, Billerica,
MA, USA), maintained at room temperature and vigor-
ously shaken (succussed) immediately before each treat-
ment. Since all experiments were performed in a double
blind and randomized manner, the initial code applied
for this studied complex (M8) remains in the Results/
Discussion sections of this article.
Animals
For in vivo experiments, 2-3 month old male C57BL/6
mice were purchased from Central Animal House of the
Federal University of Paraná (UFPR). All recommenda-
tions of the National Law (No. 6.638, November, 5,
1979) for scientific management of animals were fol-
lowed and the Institutional Animal Care Committee of
UFPR approved all related practices. All experiments
were performed at least three times in quadruplicate
and data analysis was performed in a double-blinded
manner. Experiments were carried out at Laboratório de
Pesquisa em Células Neoplásicas e Inflamatórias, UFPR,
Brazil, and at Cell Biology Unit, IPMon, Uruguay.
Cell lines
B16F10 cells
Murine melanoma cells (B16F10 - ATCC: CRL-6475;
mouse melanoma cell), were used for this study. Cells
were maintained in DMEM containing 10% FBS, 1 U/
mL penicillin, 1 μg/mL streptomycin, and 2.5 μg/mL
amphotericin at 37°C in a humidified 5%CO2
atmosphere.
MxRage 7 cells
Transformed murine embryonic fibroblasts consist of an
indicator cell line in which Cre-recombinase is driven
by the IFN-inducible Mx1 promoter that, when acti-
vated, deletes a stop cassette upstream of the eGFP cod-
ing region, resulting in the expression of eGFP. The
percentage of eGFP expressing cells, determined by
fluorescence activated cell sorting (FACS), accurately
correlates to the amount of type I IFN added to the cul-
ture [18]. This cell line was maintained at 32°C in a
humidified 5% CO2 atmosphere, using DMEM (GIBCO,
Invitrogen, Carlsbad, CA, USA) supplemented with 10%
FBS (GIBCO).
HT29
Human colon-rectal cancer cells (ATCC: HTB-38) were
stably transfected with the pNF-B-hrGFP Plasmid from
the PathDetect Signal Transduction Pathway cis-Report-
ing Systems Kit (Stratagene) Briefly, subconfluent HT29
cells were transfected with pNF-B-hrGFP plasmid
using Lipofectamine 2000 (Invitrogen) and selected with
hygromycin. After two weeks, cells were stimulated for
24 h with a pro-inflammatory cocktail (25 ng/mL TNF-
a,1 . 2 5n g / m LI L - 1 b and 3.75 ng/mL IFN-g)a n dG F P
positive cells were sorted with a MoFlo cell sorter
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tained in RPMI (GIBCO) containing 10% FBS, 1 U/mL
penicillin, 1 μg/mL streptomycin at 37°C in a humidified
5% CO2 atmosphere.
All in vitro experiments were performed at 37°C in a
humidified 5% CO2 atmosphere for 48 h. All treatments
were administered to log-phase growing cells and the
different assayed conditions were divided into: a) cells
without treatment (control culture conditions, named
“Control”); b) cells treated with vehicle (1% hydroalco-
holic solution, named “Vehicle”); or c) cells treated with
M8 (named “M8”). An initial dose of 20% of M8 treat-
ment was administered to the cells and, after 24 h, a
reinforcement dose of 1% was administered according to
a previous standard treatment protocol [10,16].
Experiments on in vitro reporter cells (MxRAGE 7 and
HT29-pNF-B-hrGFP)
The reporter cell lines MxRAGE 7 and HT29-pNF-B-
hrGFP are routinely used at CBU (IPMon) to screen
natural or synthetic compounds that interfere with type
I IFN signaling pathway and/or modulate NF-Ba c t i v -
ity. For the IFN assay, exponentially growing MxRage 7
cells were seeded in a 96-well plate and grown for 24 h
at 32°C. The cells were then cultured for 48 h in pre-
sence or absence of fixed amounts of murine IFN-a11,
with or without the vehicle or M8. Finally, cells were
harvested using trypsin, resuspended in PBS and stained
with 7-AAD to identify dead cells. Ten thousand events
were acquired and analyzed on a CyAn™ ADP Flow Cyt-
ometer (Dako, Carpinteria, CA) using Summit v4.3 soft-
ware. For the NF-B activation assay, exponentially
growing HT29 pNF-B-hrGFP cells were treated cul-
tured for 24 h in absence or presence of 3 ng/mL TNF-
a, with or without the vehicle or M8 complex, and the
percentage of positive GFP cells and the viability were
determined using CyAn™ ADP Flow Cytometer (Dako,
Carpinteria, CA) and Summit v4.3 software.
In vitro B16F10 cell experiments
Invasion activity of melanoma cells was assayed in a
transwell cell culture chamber as previously described
[19], with some modifications. Briefly, polyvinyl-pyrroli-
done-free polycarbonate inserts with an 8.0 μmp o r e
size (Corning-Costar, Cambridge, MA, USA) were pre-
coated with 5 μg of fibronectin on the reverse side and
dried at room temperature. Matrigel (containing lami-
nin, collagen type IV, heparan sulfate proteoglycan and
entactin from BD Pharmigen, San Diego, CA, USA) was
diluted to 500 μg/mL with cold PBS, applied to the
upper surface of the filter (5 μg/filter), and dried at
room temperature. Log-phase growing B16F10 cultures
were harvested by trypsin treatment, washed twice
and re-suspended to give a final concentration of
2.0 × 10
6 cel/mL in serum free DMEM medium supple-
mented with 0.1% bovine serum albumin (BSA, Sigma-
A l d r i c hC h e m i c a lC o . ,S t .L o u i s ,M O ,U S A ) .C e l l
suspensions (100 μl) were added to the upper compart-
ment of the insert chamber and incubated for 6 h at 37°
C in a humidified 5% CO2 atmosphere in the presence
or absence (control) of M8 or its vehicle. Cells derived
from the different assayed conditions were processed for
scanning electron microscopy (SEM). Cell-containing
filters were fixed with 2.5% glutaraldehyde (0.1 M caco-
dylate buffer, pH 7.2), washed with PBS and post-fixed
in 1% OsO4 for 30 min in the dark at room tempera-
ture. After washing, the cells were dehydrated using
increasing ethanol concentrations. Filter membranes
were CO2 critical point dehydrated, metalized and
observed using a JEOL JSM-6360 LV SEM.
Cultured B16F10 cells were analyzed by flow cytome-
try for cadherin, CD74 and 7-Amino-actinomycin D (7-
AAD) as viability markers and propidium iodide (PI) as
a cell cycle marker. Log-phase growing B16F10 cultures
were harvested by trypsin digestion, washed twice and
re-suspended in PBS containing 1% FBS. The harvested
cells (10
6) were incubated with anti-CD74/FITC (BD
Pharmingen, San Diego, CA, USA) in PBS containing
1% FBS for 30 min and washed three times with PBS.
For intracellular CD74 and cadherin, a simultaneous
incubation was performed with anti-CD74/FITC (BD
Pharmingen) and anti-cadherin/FITC (Vector Labs, Bur-
lingame, CA, USA) antibodies using 0.01% saponin in
the incubation buffer. Cells were also stained with
7-AAD (BD Pharmingen) for 5 min to estimate the
number of dead cells. Cell cycle was determined as
previously described [20]. Log-phase growing B16F10
cultures were detached by trypsin treatment, washed
twice with PBS and fixed in chilled 70% ethanol. After
centrifugation, the fixed cell pellet was treated with
RNAse at a concentration of 50 μg/mL (Sigma-Aldrich
Chemical Co., St. Louis, MO, USA) and stained with
50 μg/mL propidium iodide (Sigma-Aldrich) for 10 min
at room temperature. For all flow cytometry experiments,
ten thousand events were acquired on a FACSCalibur
using the CellQuest software (Becton-Dickinson), and
data were analyzed using WinMDI 2.9 software.
B16F10 lung metastasis and in vivo treatment
B16F10 melanoma cells from a 70-80% confluent mono-
layer culture were trypsinized, washed and suspended in
DMEM. 1 × 10
5 cells were then resuspended in 0.1 mL
of serum free DMEM and injected intravenously
through the tail vein of C57BL/6 mice for the develop-
ment of lung metastasis. The treatment was started 24
hr after tumor cell inoculation. Animals (n = 9 animals
per group) were treated with inhalation of M8 or vehicle
twice a day (12-12 hr) for 14 days, or were part of the
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The inhalation chamber was similar to the design pre-
viously described [21]. It nebulizes aqueous compounds
for in vivo treatment of small rodents, aiming to directly
distribute compounds to the lung, the specific patholo-
gic site. The chamber was mounted in a plastic box that
was coupled to a micropump nebulizer (Inalar - NS,
Brazil), which was situated at the inlet of the chamber.
M8 or its vehicle was nebulized through the inlet into
the chamber (Figure 1). Air was circulated from the
chamber outlet through small pores in the box. Follow-
ing a dose of 10 mL/5 mice/10 min, the mice were
removed from the chamber and allowed to equilibrate
for 15 min and then replaced in the animal facility until
the next dose was administered. After treatment, ani-
mals were subjected to euthanasia by an intraperitoneal
injection of thiopental, followed by decapitation. Blood
from each animal was collected in disodium EDTA
vacutainers (BD, San Jose, CA, USA) and was used for
immunophenotyping assays. Lungs were chirurgic
acquired, placed in Petri dishes with PBS and rapidly
analyzed (before histological fixation) with a stereomi-
croscope for the presence of black metastatic nodules.
Blood leukocytes and bone marrow cell analysis
For immunophenotyping analyses, blood aliquots con-
taining 10
6 leucokytes were incubated for 10 min with
PharM Lyse (BD) for red blood cells lysis, followed by
an 30 min incubation with anti-CD3/FITC, anti-CD4/
PE, anti-CD8/PE, anti-CD11b, anti-CD16/32 (Fc block),
anti-CD19/PE, anti-CD45 and anti-Pan-NK/PE. All anti-
bodies were monoclonal antibodies (MAbs) from BD
Pharmingen and were diluted in PBS with 1% FBS. After
the MAbs binding, cells were washed three times with
PBS and analyzed by flow cytometry using a FACSCli-
bur (BD). For each sample, ten thousand events were
acquired using the CellQuest software (BD) and data
analysis was performed using WinMDI 2.9 software.
FITC and PE isotype controls (BD Pharmingen) were
used to calibrate the cytometer before the experimental
sample acquisition. For bone marrow cells, the protocol
was performed as previously described [14]. Briefly,
femurs were dissected and cleaned. Epiphyses were
removed and the marrow was flushed with DMEM
(GIBCO). Cells (10
6) were fixed with 1% paraformalde-
hyde, washed, and incubated for 40 min with biotiny-
lated antibodies from a Mouse Lineage Panel Kit (BD,
Pharmingen): anti-CD3, anti-B220, anti-Ly6G, anti-
TER119, anti-CD11b, anti-CD11c. Samples were then
washed with PBS and incubated with 0.5 μg/mL of
streptavidin-PE (BD, Pharmingen) in PBS for 30 min
and subsequently, cells were acquired and analyzed for
blood samples as described. Blood aliquots were also
stained with May-Gründ-Giemsa (InstantProv Kit, New-
Prov, Brazil), allowing for differential counting of baso-
phils, neutrophils, eosinophils and monocytes by light
microscopy.
Lung histopathology, immunohistochemistry, and
ultrastructural pathology
After blood sampling, lungs were dissected, washed once
with PBS and fixed by immersion in 4% paraformalde-
hyde in PBS for 1 hr. After washing with PBS, lungs
were dehydrated using increasing ethanol concentra-
tions, xylene and embedded in paraffin. For histopathol-
ogy analysis, 5 μm sections of lungs were deposited on
silane coated slides. Sections were deparaffinized in
xylene, hydrated in alcohol, and incubated in 3% H2O2
Figure 1 Inhalation chamber designed to nebulize aqueous compounds for in vivo treatment of small rodents, directly distribution
compounds to the lung, the specific pathologic site. The chamber was mounted in a plastic box that was coupled into a micropump
nebulizer that was situated at the inlet of the chamber (A), and M8 was nebulized through the inlet into the chamber (B).
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Retrievagen A (pH 6.0) kit (BD Pharmingen) was used
for antigen unmasking, nonspecific binding was blocked
by 1% BSA-PBS solution and possible aldehyde groups
were blocked by 50 mM glycine-PBS. Anti-CD11c, anti-
GR-1 (BD) and anti-perlecan proteoglycan (Affinity Bio-
reagents), as well as the isotype controls (BD Pharmin-
gen), were diluted 1:50 in 0.1% BSA/PBS and incubated
on slides in a humidified chamber for 2 hr. After wash-
ing with PBS, the respective secondary biotinylated anti-
body (BD Pharmingen) was added at the same dilution
and incubated for 1 hr more, then washed, followed by
an incubation step with streptavidin-HSP (BD Pharmin-
gen) for 1 hr. After washing with PBS, MAbs binding
was revealed with a DAB Substrate kit (BD Pharmin-
gen). Slides were stained with Giemsa (EMS) and rapidly
dehydrated in ethanol, xylene and then coverslips were
mounted with entellan. Sections were scanned with a
Nikon Eclipse E200 microscope and the areas of the
highest immunostaining were imaged at (12.5 × 100)×
magnification. CD11c and GR-1 positive spots were
counted in 10 chosen fields with highest density. Perle-
can expression in tumor zones was quantified by color
area measurement by ImageJ software (NIH) to distin-
guish DAB stain from melanin, which turns color from
brown to dark green after Giemsa stain [22]. For con-
ventional histopathology analysis, a periodic acid-Schiff
(PAS) stain was performed on the same samples and
sections were scanned by a microscope at (12.5 × 40)×
or 100× magnification.
For transmission electron microscopy, a rapid proto-
col was performed as previously described [23].
Briefly, small pieces of lung tissue (1 mm
3) containing
melanoma nodules were fixed for 20-30 min with Kar-
novsky’s fixative (2% glutaraldehyde, 4% paraformalde-
hyde, 5 mM CaCl2, in 0.1 M cacodylate buffer, pH 7.2
- 7.4); they were then washed with the same buffer
a n dp o s t - f i x e dw i t h1 %o s m i u mt e t r o x i d e ,1m M
CaCl2, 0.8% potassium ferricyanide in 0.1 M cacody-
late buffer (pH 7.4) for 15 minutes and then rinsed
twice for 1 min with the same buffer. The lung pieces
were dehydrated with acetone 50%, 70%, 90% and
100% (2×) for 3 minutes each. The tissues were trans-
ferred to bean capsules containing 90% acetone and
infiltrated in epoxy resin (Epon)/acetone solution (1:1)
f o r2h r ,t h e ni np u r eE p o nf o r4h ra n d ,l a s t l y ,
e m b e d d e di nan e wE p o ns o l u t i o no v e r n i g h t .P o l y m e r -
ization was carried out for 48 hr at 60°C. Ultra-thin
sections were stained with aqueous uranyl acetate for
15 min and with lead citrate for 2 min. Samples were
visualized with a Jeol JEM 1011 transmission electron
microscope. A GATAN CCD camera and GATAN
digital micrograph software were used to obtain the
digital images.
Micrographs and statistics analysis
Micrographs obtained from immunohistochemistry and
electron microscopy were analyzed by ImageJ software
(NIH) to obtain mean/pixel values from the specific
threshold of transwell insert pores or IHC chromogen.
Data obtained from assays were transformed to conform
to a normal distribution using the equation transformed
data = x  05 . . Statistical significance of transformed
data was determined using a one-way analysis of var-
iance (ANOVA), followed by Tukey post test. Statistical
significance is presented as either P < 0.05 (*) or P <
0.01 (**). Data are representative of three independent
experiments performed in triplicate.
Results
M8 in vitro effects on B16F10 cells
First, we wanted to address the in vitro effect of M8
treatment on B16F10 cells. After 48 h exposure, viabi-
lity, cell cycle, protein expression associated with tumor
process and adhesion/invasion in matrigel were ana-
lyzed. Cell viability, assessed by 7-AAD stain, did not
show significant differences between control, vehicle and
M8 (data not shown). Cell cycle was evaluated and there
was a clear trend toward a decrease in the number of
cells in S and G2 phases; however, the data did not
reach statistical significance (p = 0.08) (data not shown).
Flow cytometry analysis of the expression pattern of
some key proteins linked with the tumoral process
showed no differences in the intracellular expression of
E-cadherin or intracellular/extracellular expression of
CD74 (data not shown). However, when the effect of
M8 treatment in adhesion and invasion in matrigel was
assessed, a promising result was observed. Electron
microscopy analysis of the invasion assay on fibronec-
tin/matrigel coated in transwell inserts with 8 μm pores
showed a decrease in B16F10 cell adhesion in matrigel
that was associated with a decrease in matrigel degrada-
tion after M8 treatment (Figure 2). ImageJ analysis of
the pores clearly shows a loss of adhesion of B16F10
cells, accompanied by a decrease in the number of cells
on the matrigel subtract. When cells were treated with
M8, there was more non-degraded matrigel obstructing
the pores, leading to a diminished number of exposed
pores. These data suggest that M8 decreases cellular
invasion.
In vivo evaluation of M8 treatment in lung metastasis
Taking into account the promising results obtained in
vitro, the next step was to evaluate the in vivo effect of
M8 in a lung metastasis model. C57BL/6 mice were
injected intravenously with B16F10 cells to develop lung
metastasis. The treatment was started 24 hr after tumor
cell inoculation and the animals were treated with M8
or vehicle twice a day for 14 days. A decrease in the
Guimarães et al. BMC Cancer 2010, 10:113
http://www.biomedcentral.com/1471-2407/10/113
Page 5 of 14number of tumoral nodules was observed in lungs after
M8 treatment (Figure 3A-D). This observation was con-
firmed by the statistical analysis of the number of tumor
nodules, which showed that the difference between the
control and the M8-treated mice was significant (***P <
0.001) (Figure 3E).
Histopathology analysis showed a difference in tumor
nodule pattern distribution, concentration and area in
lung histology sections. From a structural point of
view, it was observed that melanoma cells with polied-
ric morphology with a great amount of melanin con-
tent as cytoplasm granules or in a perinuclear
distribution. Additionally, aberrant nodular prolifera-
tion in bronchoalveolar regions, characteristic of
epithelial melanoma, was observed (Figure 4B and 4C,
respectively). After M8 treatment (Figure 4D), tumor
nodules were decreased and organized in a predomi-
nantly peripheral distribution, whereas, in control and
vehicle groups, the nodules were larger and distributed
in the lung parenchyma.
An ultrastructural overview by transmission electron
microscopy showed a characteristic pulmonary par-
e n c h y m a( F i g u r e5 ) ,i nw h i c ht h ep r e s e n c eo ft u m o r
cells with large amounts of very dense and black cyto-
plasmic pigment granules (melanosomes) is obvious.
Surrounding these cells are many dying parenchyma
cells with pyknotic nucleus (Figure 5A and 5B), char-
acteristic of apoptotic cells. Figure 5C shows a tumor
Figure 2 In vitro treatment of B16F10 cells. Untreated cells (Ctr. B16F10+), vehicle treated cells (V) and M8 treated cells (M8), respectively.
Scanning electron micrographs (SEM) of invasion assay on fibronectin/matrigel-coated transwell inserts with 8 μm pores. Original micrographs
were analyzed by ImageJ software and the total area of 8 μm pores was evaluated in pixels (Px). Black density of pores is directly proportional to
matrigel wall degradation by B16F10 cells. ImageJ analysis of pores shows the loss of adhesion of B16F10 cells, accompanied by a decrease in
cell number on the matrigel substrate, as well as the permanence of non-degraded matrigel obstructing the pores in the cells treated with M8,
diminishing the number of exposed pores.
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some granules and increased metabolic activity, evi-
denced by a euchromatic nucleus and many
mitochondria. Figure 5D shows a macrophage with
internalized melanosomes, evidence of the phagocytosis
of tumor cell products.
Peripheral blood and bone marrow cell subpopulation
analysis after M8 treatment of mice with lung metastasis
In order to determine whether the melanoma regression
was mediated by immune cells, different subpopulations
were quantified from blood and bone marrow derived
from mice with lung metastasis. Blood leukocytes
Figure 3 Lung metastasis in C57BL/6 mice induced from B16F10 tail vein injection. Figure A: Normal lung. Figure B, C and D: A mouse
with B16F10 lung metastasis, untreated, vehicle treated or M8 treated, respectively. Figure E: a = normal lung; b = untreated lung with B16F10
metastasis; c = lung with B16F10 metastasis treated with vehicle; d = lung with B16F10 metastasis treated with M8. Treatment caused a
statistically significant decrease in metastasis (***P < 0.001) and significantly decreased metastasis as compared with vehicle-treated animals
(*P < 0.05). Y axis of graph = transformed mean after normal distribution using the equation to transform data, x  05 . .
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increase in basophils and neutrophils concentrations,
but not in eosinophils or monocytes (Figure 6). After
lymphocyte immunophenotyping analyses, no significant
differences were found in B (CD3
-CD19
+), NK (CD3
-
Dx5
+), NKT (CD3
+Dx5
+), Tc (CD8
+), or Th (CD4
+)
lymphocytes in circulating blood (Figure 6). On the
other hand, cells from bone marrow showed differences
in the concentration of CD3 and CD11c positive cells,
but not in the concentration of B220, CD11b, Ly6G and
TER119 positive cells (Figure 7).
Lung immunohistopathology
The next step was to evaluate whether M8 treatment
could affect lung-infiltrated or resident granulocytes and
macrophages/dendritic cells. The concentration of those
cell populations were estimated by cell counting on
immunohistochemistry slides. Although the number of
blood granulocytes (basophils and neutrophils) was
increased after treatment, no significant differences were
found in lung peritumoral granulocyte (GR-1
+)o r
macrophages/dendritic cell (CD11c
+) number (Figure 8).
Lung samples were also analyzed by immunohistochem-
istry for perlecan expression, a heparan sulfate proteo-
glycan. After M8 treatment, perlecan expression was
significantly down regulated in tumor nodules (Figure
9A-D). This difference was more evident after quantifi-
cation by ImageJ (Figure 9E).
Discussion
Tumor cells use multiple mechanisms to escape detec-
tion and elimination by the immune system, prompting
the development of chemotherapeutic drugs that har-
ness both humoral and cellular immunity to target
Figure 4 Histopathology analysis of normal lung (A), lung metastasis from untreated mice, control (B), lung metastasis from mice
treated with the vehicle (C) and lung metastasis from mice treated with M8 (D). A significant difference was observed in tumor nodule
pattern distribution, concentration and area. After M8 treatment (D), tumor nodules (arrows) were smaller and organized in a predominantly
peripheral distribution, whereas in the control and vehicle groups the nodules were larger and distributed in the lung parenchyma (B and C,
respectively).
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effectiveness of alternative and complementary therapies
in cancer, and the few studies that have been performed
were limited in scope. Beside this, immunostimulation
by natural products has been attempted in various ani-
mal models and in human cancer patients as an adjunct
to chemotherapy [24-26].
A high diluted complex treatment in macrophages has
been shown to suppress previously elevated levels of
tumor necrosis factor-a (TNF-a), increase the activity
of NADPH oxidase and the expression of inducible
nitric oxide synthase (iNOS), and induce differential
gene expression [9-11]. Many studies have demonstrated
t h er o l eo fd i f f e r e n th i g hd iluted complexes in cancer
therapy immunomodulation [13,17,27,28]. Regarding M8
(Calcarea carbonica and associations), our previous
results showed that in vitro treatment significantly
increased macrophages/lymphocyte interaction and
effectiveness against melanoma cells [17]. Extending
these previous data to the in vivo immunotherapeutic
effect of this compound, we now demonstrate that M8
therapy prevents tumor growth and metastasis.
Figure 5 Ultrastructural overview by Transmission Electron Microscopy - Images of lungs with melanoma nodules. A: Lung cells in
panoramic view, with nucleus (N), erythrocytes (E), pyknotic nucleus (PN), melanosomes (Me); B: Lung in a panoramic view with an evident
tumor cell containing a big nucleus, melanosomes (Me) and many mitochondria; C: more details of a tumor cell, including the morphologic
characteristics of intense metabolism, a big euchromatic nucleus, many mitochondria (Mi) and melanosomes. D: an alveolar macrophage with an
euchromatic nucleus (N); many organelles, such as the endoplasmic reticulum and mitochondria, endocytic vacuoles, and internalized
melanosomes (Me); and a surface covered with many cellular projections.
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Page 9 of 14Progression of melanoma and other malignant can-
cers involves cellular changes such as the loss of E-
cadherin expression and the gain of CD74 expression,
which confer cell motility and immunologic escape,
respectively [29,30]. However, while both molecules
were analyzed in the present study, no differences
were found after M8 treatment (data not shown).
Despite this finding, scanning electron micrographs
analysis clearly showed the loss of adhesion of B16F10
cells, demonstrated by a decreased cell number on the
matrigel subtract, and the permanence of non-
degraded matrigel obstructing the pores in the cells
treated with M8, leading to a diminished number of
exposed pores (Figure 2).
Since interferon type I based immunostimulation
has been studied as an effective immunotherapy for
melanoma cases [31], we further investigated the in
vitro effect of M8 on type I IFN activity using
Figure 6 Blood leukocyte phenotyping. May-Gründ-Giemsa stain was performed to differentially count basophils, neutrophils, eosinophils and
monocytes by light microscopy. MABs for CD3/CD4, CD3/CD8, CD3/CD19, and CD3/Dx5 were used to evaluate B (CD3
-CD19
+), NK (CD3
-Dx5
+),
NKT (CD3
+Dx5
+), Th (CD3
+CD4
+), and Tc (CD3
+CD8
+) lymphocytes. a: normal mice; b: untreated mice with B16F10 lung metastasis; c: vehicle-
treated mice with B16F10 lung metastasis and d: M8-treated mice with B16F10 lung metastasis. Treatment caused a statistically significant
increase in the number of blood basophils and neutrophils (*P < 0.05). Y axis of graphs = transformed mean after normal distribution using the
equation to transform data, x  05 . .
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Page 10 of 14MxRage reporter cells [18]. When these cells were
exposed to M8, no agonist or antagonism capacity
was observed (Additional file 1: Supplementary Figure
A). Moreover, NF-B has been reported to increase
tumourigenesis by promoting anti-apoptotic activity,
chemotherapy resistance, the expression of positive
cell cycle regulators and the expression of other
survival factors [32]. However, no agonistic or antago-
nistic NF-B activation was found after M8 treatment
in the HT29 reporter model (Additional file 1: Sup-
plementary Figure B).
On the other hand, lung metastasis regression was
observed in vivo after M8 treatment (Figure 3 and 4).
In order to evaluate the mechanism of action of M8
Figure 7 Bone marrow cell phenotyping. MABs for CD3, CD11b, CD11c, B220, Ly6G and TER119 were used to evaluate T precursor cells
(CD3
+), monocyte precursors (CD11b
+), dendritic cell precursors (CD11c
+), granulocyte precursors (Ly6G
+) and erythrocyte precursors (TER119).
a: normal mice; b: untreated mice with B16F10 lung metastasis; c: vehicle-treated mice with B16F10 lung metastasis and d: M8-treated mice
with B16F10 lung metastasis. Most markers showed a normalization tendency, i.e. the values from treated mice were similar to the values
from normal mice. Y axis of graphs = transformed mean after normal distribution using the equation, to transform data, x  05 . .
Figure 8 Immunohistochemistry quantification of CD11c (monocytic/dendritic cell marker) and GR-1 (granulocytic marker) cells.
a: normal mice; b: untreated mice with B16F10 lung metastasis; c: vehicle-treated mice with B16F10 lung metastasis and d: M8-treated with
B16F10 lung metastasis. No statistically significant differences were found after developing with HSP/TMB (blue) and counting positive cells.
Y axis of graph = transformed mean after normal distribution using the equation to transform data, x  05 . .
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Page 11 of 14in vivo, the level of immune cells was analyzed. Pre-
vious studies have shown that this category of medica-
ment increases blood lymphocytes such as TCD4,
TCD8 and NK, which are associated with tumor
regression in an albino Swiss mice/Sar-180 model [13].
In a C57BL/6 mice/B16F10 model, there was no signif-
icant difference in lymphocyte level from blood and
bone marrow (Figure 6 and 7). However, the difference
between the results obtained with the C57BL/6 strain
and albino Swiss strain may be because the first mouse
model has an intrinsic and well established innate and
Th1 response that limits its use immunological ques-
tions [33]. On the other hand, it is the most used mur-
ine model to simulate metastatic melanoma because it
Figure 9 Perlecan quantification in metastatic nodules by immunohistochemistry. Staining melanocytic samples with Giemsa results in a
uniform dark green/blue coloration of melanin that is easily distinguishable from the DAB precipitate of the HSP reaction. DAB-specific threshold
selection from selected tumor areas was performed by ImageJ software (red/orange selection in Figures A, B, C and D), and total selected area
was quantified and statistically analyzed (E). a: normal mice; b: untreated mice with B16F10 lung metastasis; c: vehicle-treated mice with B16F10
lung metastasis and d: M8-treated mice with B16F10 lung metastasis. M8 treatment resulted in a statistically significant decrease in heparan
sulfate proteoglycan expression. A = Normal lung; B = B16F10 positive control; C = Vehicle treatment; D = M8 treatment. Y axis of graphs =
transformed mean after normal distribution using the equation to transform data, x  05 . .
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Page 12 of 14reflects several characteristics of human metastatic
melanoma, and because B16F10 cell inoculation is only
compatible with this strain [34]. An increase in
the number of circulating basophils and neutrophils
was observed after M8 treatment. Basophils and neu-
trophils have been recently appointed as promissory
innate cells to be targeted for anti-cancer treatment
because are the first cells able to detect tissue abnorm-
alities as tumor necrosis or growth damages tissue
[35]. There was no significant difference in bone
marrow leukocytes number, but there was a clear ten-
d e n c yf o rC D 4a n dC D 1 1 cm a r k e r s( F i g u r e7 )t ob e
close to the levels seen in normal mice, demonstrating
a “normalization” of bone marrow cell production.
This study provides some information to clarify the
mechanism by which M8 treatment affects melanoma
metastasis in this model. We observed a decrease in
perlecan expression and a direct inhibition of cancer
cell adhesion and invasion (Figure 2 and 9). Perlecan
is an important component of basement matrix and
its expression correlates strongly with the expression
of several metastatic, angiogenic and invasive factors
in tumor cells, particularly melanoma cells. Tumor-
derived perlecan is distributed throughout its matrix
and creates a microenvironment that favors neovascu-
larization, tumor growth and invasion [36,37]. Perle-
can has been identified as a potential therapeutic
target for the treatment of metastatic cancer because
it is a necessary molecule for tumor vessels’ structural
integrity and forms the major storage site of neovascu-
larization factor FGF-2 [7,38]. Despite this, the inhibi-
tion of adhesion of extracellular matrix molecules in
melanoma cells causes cell rounding, loss of survival
and apoptosis [39]. This result is corroborated by the
invasion assay, which showed a loss of adhesion of
B16F10 cells to the Matrigel substrate because of a
decrease in the ECM proteolysis ability of the cells
(Figure 2).
Conclusion
Taken together, these results may explain the possible
tumor cell dormancy and decrease in tumor nodule
number and volume caused by M8 treatment. These
findings suggest that M8 is a promising therapy that
m a yi m p r o v et h ei n n a t ei m m u n er e s p o n s ea g a i n s t
tumor cells, decreasing the cell adhesion or invasion of
malignant cells or even inducing direct dormancy in
malignancies. Further studies are necessary to clarify the
precise and detailed mechanism of M8 treatment in
anti-tumor effects in melanoma and its use as combina-
tion-therapy candidate used in addition with conven-
tional medicines.
Additional file 1: In vitro type I IFN and NF-B assays. In order to
verify the possible influence of M8 treatment in type I IFN and/or NF-B
signaling, a preliminary screening was performed. Quantitative
examination of M8 treated Mx-RAGE and HT29 cells by flow cytometry
showed no statistically significant differences in type I IFN and/or NF-B
activity, respectively (Supplementary Figures A and B, respectively).
Supplementary Figure A:M 8in vitro treatment of MxRage cells, a
reporter cell line to evaluate type I IFN activity. No significant differences
were found in GFP expression during the screening. Both negative and
positive circumstances were evaluated for the ability to increase IFN
production (compound alone) and the ability to decrease IFN production
(compound plus IFN-a). GFP expression was evaluated by flow cytometry
analysis of treated cells. No differences in cell viability were detected by
7-AAD stain. Supplementary Figure B: The HT29-pNF-B-hrGFP reporter
cell line was used to evaluate the activation of NF-B after in vitro
treatment with M8. No significant differences were found in NF-B
activation after treatment. Both negative and positive scenarios were
evaluated for the ability to activate NF-B (compound alone) and the
ability to decrease NF-B activation (compound plus TNF-a). GFP
expression was evaluated by flow cytometry of treated cells. No
differences in cell viability were detected by 7-AAD stain. Y axis of graphs
= transformed GFP mean after normal distribution using the equation to
transform data, x  05 . .
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